Labgenomics Co

Labgenomics Co Current Assets

The Current Assets of Labgenomics Co (084650.KQ) as of Nov 14, 2026 is 2.78 B KRW. In the previous year, Current Assets was 134.57 B KRW — a change of -97.93% (lower).

Current Assets

2.78 BKRW

YoY

-97.93%

Last updated:

Current Assets of Labgenomics Co is 2025 2.78 B KRW. Current Assets of Labgenomics Co was 2024 134.57 B KRW. It decreases by -97.93% lower compared to the previous year.

The Labgenomics Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
31.20 B KRW
Jan 1, 2019
33.34 B KRW
Jan 1, 2020
87.31 B KRW
Jan 1, 2021
170.76 B KRW
Jan 1, 2022
174.27 B KRW
Jan 1, 2023
158.81 B KRW
Jan 1, 2024
134.57 B KRW
Jan 1, 2025
2.78 B KRW
The Labgenomics Co Current Assets history
YEARCurrent AssetsYoY
2.78 BKRW-97.93%
134.57 BKRW-15.26%
158.81 BKRW-8.87%
174.27 BKRW+2.06%
170.76 BKRW+95.58%
87.31 BKRW+161.86%
33.34 BKRW+6.86%
31.20 BKRW+40.36%
22.23 BKRW-9.58%
24.58 BKRW+82.55%
13.47 BKRW+14.30%
11.78 BKRW-6.66%
12.62 BKRW+37.55%
9.18 BKRW+7.40%
8.55 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Current Assets of Labgenomics Co is 2.78 B KRW in 2025.

Current Assets of Labgenomics Co changed from 134.57 B KRW to 2.78 B KRW, representing a -97.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labgenomics Co

All Key Metrics — Labgenomics Co